Compare AbbVie Inc (ABBV) vs Check Point Software Technologies Ltd (CHKP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Check Point Software Technologies Ltd — how do they compare? AbbVie Inc trades at $253.6 (market cap $449.91B), while Check Point Software Technologies Ltd trades at $136.37 (market cap $14.43B). The key difference: AbbVie Inc is far larger — about 31.2× Check Point Software Technologies Ltd's market cap, and AbbVie Inc pays a 2.72% dividend while Check Point Software Technologies Ltd pays none. Which is the better fit depends on your goals.
| ABBV | CHKP | |
|---|---|---|
Market Cap | $449.91B | $14.43B |
Sector | Health | Technology |
52-Week High | $261.07 | $231.23 |
52-Week Low | $184.85 | $112.47 |
Enterprise Value | $513.38B | $13.64B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
CHKP trades at $138.87, up 1.68% today, with a bullish technical outlook supported by moving averages and strong support at $136. The company demonstrates robust fundamentals with a 38.37% net income margin, consistent earnings beats, and strategic AI partnerships enhancing its cybersecurity offerings. Recent news highlights ESG reporting and cloud security expansions.
Outlook remains positive with a consensus price target of $148.73, though risks include insider sales and legal investigations. The stock offers growth potential from AI integration but faces competitive and regulatory headwinds that warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Check Point Software Technologies Ltd
Check Point is a global leader in cybersecurity solutions. It provides comprehensive protection against advanced cyber threats for corporate networks, cloud environments, mobile devices, and critical infrastructure.
Read more on CHKP →
